

[Back to Search Results](#)

 [Description](#)

 [Details](#)

 [Sub-Projects](#)

 [Publications](#)

 [Patents](#)

 [Outcomes](#)

 [Clinical Studies](#)

 [News and More](#)

 [History](#)

 [Similar Projects](#)

Structure-based Vaccine Design for CCHFV

Project Number
1R01AI152246-01

Contact PI/Project Leader
MCLELLAN, JASON SCOTT[Other PIs](#)

Awardee Organization
UNIVERSITY OF TEXAS, AUSTIN

 Share 

Description

Abstract Text

Project Summary/Abstract Crimean-Congo hemorrhagic fever virus (**CCHFV**) causes a life-threatening tick-borne disease in humans. The disease presents as a severe form of hemorrhagic fever with a case fatality rate of 10–40%. **CCHFV** outbreaks have spanned a wide geographic area ranging from Western and Central Asia, the Middle East, Africa and Southern Europe. Increasing global temperatures, migratory birds, and the international livestock trade have all potentially contributed toward the spread of Hyalomma ticks—the primary vector for **CCHFV**. Expanding endemic zones, widespread morbidity and significant mortality make **CCHFV** an acute threat to public health and thus is listed as a NIAID Category A priority pathogen. The viral genome encodes a glycoprotein precursor that is processed into two structural glycoproteins—Gn and Gc—and two secreted glycoproteins—a mucin-like domain and GP38. Protective antibodies have been isolated that target Gc or GP38, suggesting that these two proteins should be given priority for vaccine development. Here we propose to engineer Gc- and GP38-based immunogens that focus the immune response onto broadly conserved epitopes that are capable of eliciting protective antibody responses. To accomplish our goal, we will structurally characterize **CCHFV** glycoproteins and their interactions with human-derived antibodies, rationally engineer vaccine antigens based in part on the structural information, and characterize the immune responses elicited by these antigens in animal models. These results will be used to guide further improvements of the immunogens, including display on self-assembling multi-valent nanoparticles, and the most promising candidates will be evaluated in a lethal murine model of **CCHFV** challenge. Given our expertise, unique reagents, and preliminary data, we are confident that we can deliver a state-of-the-art subunit vaccine candidate with the potential to induce cross-reactive protective antibodies, thereby satisfying an unmet need against this NIAID Category A tick-borne pathogen.

Public Health Relevance Statement

Project Narrative Crimean-Congo hemorrhagic fever is the most widespread tick-borne viral disease in humans with case-fatality rates of 10–40%. Here we propose to employ structure-based vaccine design principles to engineer immunogens that induce cross-reactive protective antibodies. Our studies will provide insight into the structures and antigenicity of CCHFV glycoproteins and will deliver a bona fide vaccine candidate against a NIAID Category A pathogen.

NIH Spending Category

- Biodefense
- Bioengineering
- Biotechnology
- Emerging Infectious Diseases
- Immunization
- Infectious Diseases
- Nanotechnology
- Prevention
- Vaccine Related
- Vector-Borne Diseases


Project Terms

- Acute
- Africa
- Animal Model
- Antibodies
- Antibody Response
- Antibody Therapy
- Antigens
- Antiviral Agents
- Case Fatality Rates
- Categories
- Category A pathogen
- Cells
- Central Asia
- Chimeric Proteins
- Complex
- Coronavirus
- Crimean Hemorrhagic Fever
- Crimean-Congo Hemorrhagic Fever Virus
- Crystallization
- Data
- Data Protection
- Disease
- Disease Outbreaks
- Dyes
- Engineering
- Epitope Mapping
- Epitopes
- Evaluation
- Family
- Filovirus
- Funding
- Genome
- Geographic Locations
- Glycoproteins
- Goals
- Human
- IFNAR1 gene
- Immune response
- Immunocompromised Host
- Immunologics
- Incidence
- International
- Laboratories
- Laboratory Animal Models
- Life
- Livestock
- Maps

[Read More](#)

Details

Contact PI/ Project Leader


Name
[MCLELLAN, JASON SCOTT](#) 
Title
ASSOCIATE PROFESSOR

Other PIs

Name
[CHANDRAN, KARTIK](#) 

Program Official

Name
ALARCON, RODOLFO M
Contact
rodolfo.alarcon@nih.gov

 Thank you for your feedback!

[Back to Search Results](#)

 [Description](#)

 [Details](#)

 [Sub-Projects](#)

 [Publications](#)

 [Patents](#)

 [Outcomes](#)

 [Clinical Studies](#)

 [News and More](#)

 [History](#)

 [Similar Projects](#)

Structure-based Vaccine Design for CCHFV

Project Number 1R01AI152246-01		Contact PI/Project Leader MCLELLAN, JASON SCOTTOther Pls		Awardee Organization UNIVERSITY OF TEXAS, AUSTIN	
UNIVERSITY OF TEXAS, AUSTIN		BIOLOGY		TX	
City AUSTIN		Organization Type SCHOOLS OF ARTS AND SCIENCES		Congressional District 10	
Country UNITED STATES (US)					
Other Information					
FOA RFA-AI-19-037		Administering Institutes or Centers NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES		Project Start Date	25-June-2020
Study Section Special Emphasis Panel[ZAI1 FDS-M (M1)]		DUNS Number 170230239	CFDA Code 855	Project End Date	31-May-2025
Fiscal Year 2020	Award Notice Date 25-June-2020			Budget Start Date	25-June-2020
				Budget End Date	31-May-2021

Project Funding Information for 2020

Total Funding \$441,966	Direct Costs \$351,007	Indirect Costs \$90,959
Year	Funding IC	FY Total Cost by IC
2020	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$441,966

NIH Categorical Spending		Click here for more information on NIH Categorical Spending
Funding IC	FY Total Cost by IC	NIH Spending Category
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES	\$441,966	Biodefense; Bioengineering; Biotechnology; Emerging Infectious Diseases; Immunization; Infectious Diseases; Nanotechnology; Prevention; Vaccine Related; Vector-Borne Diseases;

 Sub Projects

No Sub Projects information available for 1R01AI152246-01

 Publications

No Publications available for 1R01AI152246-01

 Patents

No Patents information available for 1R01AI152246-01







 Outcomes

The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.

No Outcomes available for 1R01AI152246-01

Thank you for your feedback!

[Back to Search Results](#)

-  [Description](#)
-  [Details](#)
-  [Sub-Projects](#)
-  [Publications](#)
-  [Patents](#)
-  [Outcomes](#)
-  [Clinical Studies](#)
-  [News and More](#)
-  [History](#)
-  [Similar Projects](#)

Structure-based Vaccine Design for CCHFV

Project Number
1R01AI152246-01

Contact PI/Project Leader
MCLELLAN, JASON SCOTT[Other PIs](#)

Awardee Organization
UNIVERSITY OF TEXAS, AUSTIN

News and More

Related News Releases

No news release information available for 1R01AI152246-01

History

No Historical information available for 1R01AI152246-01

Similar Projects

No Similar Projects information available for 1R01AI152246-01

Thank you for your feedback!